Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Authors
Drilon, ABarlesi, F
De Braud, F
Cho, BC
Ahn, MJ
Siena, S
Krebs, Matthew G
Lin, CC
John, T
Tan, DSW
Seto, T
Dziadziuszko, R
Arkenau, HT
Rolfo, C
Wolf, J
Ye, C
Riehl, T
Eng, S
Doebele, RC
Affiliation
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,Issue Date
2019
Metadata
Show full item recordCitation
Drilon A, Barlesi F, De Braud F, Cho B, Ahn M, Siena S, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Cancer Res. 2019;79(13).Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2019-CT192Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2019-CT192Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2019-CT192